文献速递免疫规划妇幼与学校卫生

10价肺炎球菌H流感嗜血杆菌蛋白D结合疫苗对儿童肺炎的效果:整群随机试验

Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
PubMed 文献 · Vaccine · 2018-08-23

芬兰全国性整群随机双盲试验纳入47366名儿童,比较PHiD-CV10与肝炎疫苗对照。疫苗对医院诊断肺炎的总VE为27%(95%CI 14%,38%),对影像学确诊肺炎的VE在45%至56%之间。PHiD-CV10显著降低婴幼儿和低龄儿童肺炎疾病负担。

要点

  • 医院诊断肺炎总VE为27%(95%CI 14%,38%),不同入组月龄VE为23%至32%。
  • 影像学确诊肺炎(WHO标准)VE为45%(95%CI 26%,60%)至56%(95%CI 14%,77%)。
  • 各月龄队列每1000人年肺炎减少3.4、4.7和2.5例。

核心结论

  • PHiD-CV10接种显著降低婴幼儿和低龄儿童肺炎疾病负担。

研究设计与样本

  • 全国性、整群随机、双盲试验;2009年2月至2010年10月入组47366名儿童;PHiD-CV10组52个整群,肝炎疫苗对照组26个整群;随访至2011年底,盲法意向性分析。

主要发现

  • 医院诊断肺炎总VE为27%(95%CI 14%,38%);入组年龄<7月、7-11月、12-18月组VE分别为32%(95%CI 3%,52%)、23%(95%CI -5%,44%)和27%(95%CI 14%,38%)。
  • 影像学确诊肺炎(WHO标准)VE在<7月、7-11月、12-18月组分别为45%(95%CI 26%,60%)、56%(95%CI 14%,77%)和48%(95%CI 2%,73%)。
  • 医院诊断肺炎每1000人年减少3.4、4.7和2.5例,分别对应入组年龄<7月、7-11月和12-18月组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines have potential to prevent significant proportion of childhood pneumonia. Finnish Invasive Pneumococcal disease vaccine trial was designed to assess the vaccine effectiveness (VE) of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against several outcomes. We now report results for pneumonia. METHODS: In this nationwide, cluster-randomised, double-blind trial, children younger than 19 months received PHiD-CV10 in 52 clusters or hepatitis vaccines as control in 26 clusters. Infants younger than 7 months at the first vaccination received either 3+1 or 2+1 vaccination schedule, children aged 7-11 months received 2+1, and those 12-18 months of age two-dose schedule. All hospitalizations and outpatient visits to hospital associated with ICD-10 codes compatible with pneumonia were identified through the National Care Register and 1-3 frontal chest X-ray images per event were collected. External readers who were unaware of the patients' vaccination status retrospectively interpreted the images. The evaluated outcomes were hospital-diagnosed, hospital-treated pneumonia as primary diagnosis, and radiologically confirmed pneumonia during the blinded, intention-to-treat follow-up period from the first vaccination to the end of 2011. Total VE was calculated as 1 minus rate ratio of all pneumonia episodes. RESULTS: 47 366 children were enrolled from February 2009, to October 2010. VE against all episodes of hospital-diagnosed pneumonia was 27% (95% confidence interval [CI]: 14%, 38%), 32% (95% CI: 3%, 52%), and 23% (95% CI: -5%, 44%) in subjects enrolled at age <7, 7-11, and 12-18 months, respectively. Corresponding rate reductions were 3.4, 4.7, and 2.5 per 1000 person-years. VE estimates against pneumonia with alveolar consolidation or pleural effusion (WHO criteria) in the three cohorts were 45% (95% CI: 26%, 60%), 56% (95% CI: 14%, 77%), and 48% (95% CI: 2%, 73%), respectively. CONCLUSION: PHiD-CV10 vaccination remarkably reduced disease burden due to pneumonia in infants and young children. CLINICAL TRIAL REGISTRATION: Main trial NCT00861380, nested carriage and otitis media trial NCT00839254 (ClinicalTrials.gov).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kilpi TM, Jokinen J, Puumalainen T, et al. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial. Vaccine. 2018. PMID: 30145098. doi:10.1016/j.vaccine.2018.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。